Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Liabilities and Shareholders Equity (2019 - 2025)

Allogene Therapeutics' Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $439.8 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 25.35% year-over-year to $439.8 million; the TTM value through Sep 2025 reached $2.0 billion, down 20.21%, while the annual FY2024 figure was $548.7 million, 14.64% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $439.8 million at Allogene Therapeutics, down from $470.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.2 billion in Q1 2021 and bottomed at $439.8 million in Q3 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $746.9 million (2023), against an average of $775.1 million.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 71.24% in 2021 before it fell 27.25% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.1 billion in 2021, then dropped by 21.82% to $821.6 million in 2022, then fell by 21.76% to $642.8 million in 2023, then dropped by 14.64% to $548.7 million in 2024, then dropped by 19.85% to $439.8 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Liabilities and Shareholders Equity are $439.8 million (Q3 2025), $470.6 million (Q2 2025), and $508.0 million (Q1 2025).